The company didn't quite meet expectations for either trailing results or full-year guidance.Cancer drug developer Y-mAbs Therapeutics (YMAB -11.24%) didn't exactly kick off the stock trading week on a high note. The company's shares closed the day more than 11% lower in price, following the release of its latest set of quarterly results. That contrasted unfavorably with the performance of the bellwether S&P 500 index, which flatlined that session.A double miss for the second quarterY-mAbs is a commercial-s ...